The Uveitis Podcast offers a unique platform for healthcare professionals and patients alike to deepen their understanding of uveitic diseases and explore innovative approaches to their management.
Dr. Nisha Acharya from the F.I. Proctor Foundation at University of California, San Francisco, joins the podcast to explain what is uveitis, who gets it, and what causes it.
Dr. Eric Suhler from Casey Eye Institute at Oregon Health & Science University discusses the role of systemic immunomodulatory therapy in the management of noninfectious uveitis.
Dr. Sunil Srivastava from Cleveland Clinic's Cole Eye Institute and Dr. Steven Yeh from the Stanley M. Truhlsen Eye Institute at the University of Nebraska discuss the role of local therapy in the management of noninfectious uveitis.
In the landscape of ophthalmology and epidemiology, Dr. Nisha Acharya stands as a beacon of excellence, renowned for her profound expertise and tireless dedication to advancing the understanding and treatment of ocular inflammatory diseases. Holding the distinguished Elizabeth C. Proctor Professorship at the University of California San Francisco, Dr. Acharya's contributions extend far beyond the confines of academia, profoundly impacting the lives of countless individuals afflicted by uveitis and related conditions.
With a clinical focus centered on uveitis and ocular inflammatory diseases, Dr. Acharya exemplifies the epitome of specialized care, offering patients not only expert diagnosis and treatment but also a compassionate understanding of the challenges they face. Her commitment to excellence is evident in every aspect of her work, from pioneering research endeavors to leading-edge clinical trials aimed at evaluating the efficacy of novel treatment modalities.
At the forefront of epidemiological research, Dr. Acharya's investigations into the prevalence and risk factors associated with ocular inflammatory conditions have shed invaluable light on these complex diseases, guiding clinical practice and public health initiatives alike. As Principal Investigator of the NIH-funded First-line Antimetabolites for Steroid-Sparing Treatment (FAST) Trial, she leads a multidisciplinary team in a groundbreaking endeavor to redefine the standard of care for uveitis patients nationwide.
Not content with mere innovation, Dr. Acharya is also instrumental in driving standardization efforts within the field, serving as a key figure in the Standardization of Uveitis Nomenclature working group. Her leadership role in the Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial underscores her unwavering commitment to rigorous scientific inquiry and evidence-based practice.
Beyond her scholarly pursuits, Dr. Acharya's influence extends to the highest echelons of professional societies, where she plays an integral role in shaping the future of ophthalmology. As a member of the executive committee of the American Uveitis Society and chair of the American Academy of Ophthalmology Knowledge Base Panel for Uveitis, she champions the dissemination of knowledge and best practices, ensuring that practitioners across the nation are equipped to deliver the highest standard of care to their patients.
OCT 27, 2022 by Nisha Acharya, MD, Andrew R Carey, Matthew Timothy Feng, Lorraine M Provencher, Rajesh C Rao, Edmund Tsui
Recorded in front of a live audience at the AAO 2022 Annual Meeting in Chicago, this episode features Dr. Nisha Acharya discussing her recent Ophthalmology arti...
NOV 03, 2023 by Arthi Ganesh Venkat, MD, Nisha Acharya
Dr. Nisha Acharya, one of the panelists on the Uveitis section at Retina Subspecialty Day, has a conversation with Dr. Arthi Venkat about topics to be discussed...
APR 15, 2022 by Matthew Timothy Feng, MD, Edmund Tsui, Nisha Acharya
Dr. Matthew Feng is joined by co-host Dr. Edmund Tsui to discuss what's new in our understanding of zoster, vaccinations, and more with Dr. NishaAcharya from...
OCT 17, 2019 by Rahul N Khurana, MD, Nisha Acharya
In this interview from AAO 2019, Dr. NishaAcharya presents results from her NEI-funded trial comparing 2 commonly used, steroid-sparing, immunosuppressive drug...
JUL 13, 2020 by Jayanth S Sridhar, MD, Nisha Acharya
Drs. Nisha Acharya joins the program to discuss results of the multicenter FAST study, comparing methotrexate and mycophenolate mofetil for noninfectious uveiti...
SEP 06, 2022 by Nisha Acharya, MD, Paisan Ruamviboonsuk, Gyan Prakash MBA PHD, Ido Didi Fabian, Carol L Shields
Global Eye Health: The Future of Global Eye Research Collaboration Presentation. Moderated by Drs. Nisha Acharya and Paisan Ruamviboonsuk with presentations
NOV 09, 2023 by Edmund Tsui, MD, Nisha Acharya, Douglas A Jabs, MBA
Drs. Nisha R. Acharya and Douglas A. Jabs discuss landmark findings of the Macular Edema Ranibizumab versus Intravitreal Anti-inflammatory Therapy (MERIT) trial...
JUN 29, 2020 by Virginia Miraldi Utz, MD, Sheila Therese Angeles-Han MD MS, Nisha Acharya, Hatice N Sen
Dr. Utz moderates this virtual journal club with Drs. Angele-Han, Acharya, and Sen. Articles included: 2019 American College of Rheumatology/Arthritis Foundatio...
FEB 13, 2024 by Christopher R Henry, MD, Ghazala A Datoo O'Keefe, Edmund Tsui, Nisha Acharya, Douglas A Jabs, MBA, Parisa Emami Naeini, Shilpa Kodati, Arjun B Sood
In this webinar, Drs. Acharya, Emami, Henry, Jabs, Kodati, O'Keefe, Sood, and Tsui, provide cases centered around four of the latest uveitis-related clinical...
Presentations / Presentation
In the landscape of ophthalmology and epidemiology, Dr. Nisha Acharya stands as a beacon of excellence, renowned for her profound expertise and tireless dedication to advancing the understanding and treatment of ocular inflammatory diseases. Holding the distinguished Elizabeth C. Proctor Professorship at the University of California San Francisco, Dr. Acharya's contributions extend far beyond the confines of academia, profoundly impacting the lives of countless individuals afflicted by uveitis and related conditions.
With a clinical focus centered on uveitis and ocular inflammatory diseases, Dr. Acharya exemplifies the epitome of specialized care, offering patients not only expert diagnosis and treatment but also a compassionate understanding of the challenges they face. Her commitment to excellence is evident in every aspect of her work, from pioneering research endeavors to leading-edge clinical trials aimed at evaluating the efficacy of novel treatment modalities.
